Product Pipeline with Competitive Advantage!
CEVEC develops an early-stage pipeline of biopharmaceutical difficult-to-express proteins with commercially attractive markets and well-established biological targets. All projects aim at improved biological activity and/or half-live compared to 1st generation molecules and address an unmet need:
Either a recombinant version does not yet exist as a therapeutic agent or the recombinant version so far fails to meet therapeutic requirements.
Our first CAP® cell derived molecule entering a clinical Phase I trial has been codeveloped with Alloksys Life Science BV (Netherlands), highlighting the successful regulatory approval of CAP®-Technology. Promising additional candidate molecules are in later preclinical development and ready to follow.